Hims & Hers Health Inc’s recently made public that its Chief Financial Officer Okupe Oluyemi unloaded Company’s shares for reported $0.7 million on May 15 ’25. In the deal valued at $60.22 per share,11,581 shares were sold. As a result of this transaction, Okupe Oluyemi now holds 113,816 shares worth roughly $7.1 million.
Then, Dudum Andrew sold 128,127 shares, generating $7,482,414 in total proceeds. Upon selling the shares at $58.40, the Chief Executive Officer now owns 89,311 shares.
Before that, Dudum Andrew sold 47,534 shares. Hims & Hers Health Inc shares valued at $2,768,974 were divested by the Chief Executive Officer at a price of $58.25 per share. As a result of the transaction, Dudum Andrew now holds 285,194 shares, worth roughly $17.78 million.
TD Cowen downgraded its Hims & Hers Health Inc [HIMS] rating to a Hold from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who decreased its forecast for the stock in mid February from “an Overweight” to “an Equal-weight”. Citigroup also remained covering HIMS and has decreased its forecast on January 10, 2025 with a “Sell” recommendation from previously “Neutral” rating. BTIG Research started covering the stock on January 07, 2025. It rated HIMS as “a Buy”.
Price Performance Review of HIMS
On Monday, Hims & Hers Health Inc [NYSE:HIMS] saw its stock fall -3.57% to $62.34. Over the last five days, the stock has gained 12.91%. Hims & Hers Health Inc shares have risen nearly 157.82% since the year began. Nevertheless, the stocks have risen 350.43% over the past one year.
How much short interest is there in Hims & Hers Health Inc?
A steep rise in short interest was recorded in Hims & Hers Health Inc stocks on 2025-04-30, growing by 4.54 million shares to a total of 62.31 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 57.77 million shares. There was a rise of 7.29%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 17, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $42 price target.
